易于使用的本佐-三醇基 thiazole 衍生物作为新型蒂米丁酸化酶和α-葡萄糖酶抑制剂:实验和计算方法
Shoaib Khan1, Rafaqat Hussain2, Yousaf Khan3
1Department of Chemistry, Abbottabad University of Science and Technology (AUST), Abbottabad 22500, Pakistan.
Enzyme and microbial technology
|June 25, 2024
概括
新的佐醇化三醇衍生物显示出强烈的抑制作用对胺酸酸化酶和α-葡萄糖酶酶. 这些新型化合物表现出有希望的类似药物的特性,表明它们的潜在治疗应用.
科学领域:
- 药用化学 医学化学
- 酶学 是一种酶学.
- 药物发现 药物发现 药物发现
背景情况:
- 蒂米丁酸化酶 (TP) 和α-葡萄糖酶 (α-G) 是涉及各种疾病的关键酶.
- 开发这些酶的新兴抑制剂对于治疗干预至关重要.
研究的目的:
- 为了合成和评估基于佐醇化三醇支架的新醇衍生物.
- 评估这些衍生物对TP和α-葡萄糖酶的抑制潜力.
主要方法:
- 新型 thiazole 衍生物的合成.
- 在体外酶抑制测定TP和α-葡萄糖酶.
- 分子对接研究以阐明结合相互作用.
- ADMET (吸收,分布,新陈代谢,分泌,毒性) 预测药物相似性.
主要成果:
- 几种合成的醇衍生物显示出对TP和α-葡萄糖酶的显著抑制活性.
- 化合物A,B和C表现出强烈的抑制作用,IC50值与标准药物相当或优于标准药物.
- 分子对接和ADMET研究支持了最活性化合物的药物状性质和结合相互作用.
结论:
- 新型西醇化三醇衍生物代表了TP和α-葡萄糖酶抑制剂开发的有前途的化合物类.
- 这些发现需要进一步研究与这些酶相关的疾病中的潜在治疗应用.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Antihypertensive Drugs: Thiazide-Class Diuretics
598
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
598
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Oral Hypoglycemic Agents: Sulfonylureas
200
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
200


